PDF herunterladen
Aktuelle Urol 2013; 44(01): 33-39
DOI: 10.1055/s-0032-1331727
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Die Ejaculatio praecox in der urologischen Praxis

Premature Ejaculation in Urological Routine Practice
M. J. Mathers
1   PandaMED Remscheid, Urologische Kooperationspraxis der Klinik für Urologie und Kinderurologie, Helios Klinikum Wuppertal, Universität Witten/Herdecke
,
F. Sommer
2   Klinik und Poliklinik für Urologie, Institut für Männergesundheit, Universitätsklinikum Hamburg-Eppendorf
,
S. Degener
3   Klinik für Urologie und Kinderurologie, Helios Klinikum Wuppertal, Universität Witten/Herdecke
,
A. S. Brandt
3   Klinik für Urologie und Kinderurologie, Helios Klinikum Wuppertal, Universität Witten/Herdecke
,
S. Roth
3   Klinik für Urologie und Kinderurologie, Helios Klinikum Wuppertal, Universität Witten/Herdecke
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
04. Februar 2013 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Auch in der allgemein-urologischen Praxis ist die Ejaculatio praecox (EP) eine häufige männliche Sexualbeschwerde oder -störung. Die Häufigkeit in den einzelnen Praxen ist sehr unterschiedlich. In größeren Studien ist die Prävalenz stark von der geltenden Definition abhängig und bewegt sich zwischen 3% und 25%. Subjektiv ist die Unfähigkeit, die Ejakulation zu verzögern und der daraus resultierende Leidensdruck für den Patienten und dessen Partner relevant. Als objektivierbare Hilfsgröße dient die intravaginale Latenzzeit (IELT). In der täglichen Routinepraxis ist dieser objektive Parameter jedoch nicht praktikabel. Klinisch haben sich 2 Fragebögen durchgesetzt: Premaure Ejaculation Profile und Index of Premature Ejaculation. Studien konnten zeigen, dass die Selbsteinschätzung von Patienten relativ gut mit der objektiven, mittels Stoppuhr gemessenen IELT, korreliert. Pharmakologisch werden neben topischen Anästhetika vor allem selektive Serotonin-Wiederaufnahmehemmer (SSRI) und das seit 2009 in Deutschland zugelassene Medikament Dapoxetin eingesetzt. In Anwendung (täglich oder on-demand) und vor allem Wirkung (x-fache Verlängerung der IELT) unterscheiden sich die Medikamente stark. Dieser Artikel beschäftigt sich mit der für die tägliche Arbeit relevanten Definition der EP, der Prävalenz, Ätiologie und Neurophysiologie und auch mit der klinischen Vorgehensweise. Die verschiedenen pharmakologischen Therapiemöglichkeiten werden unter Berücksichtigung der Leitlinie der International Society for Sexual Medicine diskutiert.

Abstract

Premature ejaculation is a frequent male sexual complaint or sexual disturbance found in urological practices and outpatient units. The frequency in the individual practices varies considerably. In large studies the prevalence is strongly dependent on the definition and ranges between 3% and 25%. Subjectively, the inability to delay ejaculation and the distress resulting from it, is relevant for the patient and his partner. Intravaginal ejaculation latency time (IELT) is used as an objective parameter. Nevertheless, in the everyday routine practice this objective parameter is not practical. Clinically 2 questionnaires have asserted themselves (Premature Ejaculation Profile and Index of Premature Ejaculation). Studies have shown that the self-assessment of patients correlates relatively well with the objective IELT measured by means of a stopwatch. Beside topical anaesthetics and elective serotonin reuptake inhibitors (SSRI), especially Dapexetine which has been approved in Germany since 2009, are treatment options. These drugs differ particularly in their use (daily or on-demand) and their effectiveness (measured by x-fold increase of IELT). This article deals with the clinical approach to EP. Beside the definition, prevalence, aetiology and neurophysiology of EP, the different pharmacological therapies as well as the guidelines of the International Society for Sexual Medicine are discussed.

Schlüsselwörter

Ejaculatio praecox - Definition - Diagnostik - Therapie - SSRI - Dapoxetin

Key words

premature ejaculation - definition - diagnosis - therapy - SSRI - dapoxetin

Editorial Comment zur Übersicht

 

  • Literatur

  • 1 Mathers MJ, Sommer F, Sperling H et al. Ejaculatio praecox – Kritische Anmerkungen und deren Umsetzung in der täglichen. Praxis 2011; 18: 65-71
    PubMedGoogle Scholar
  • 2 Rowland D, McMahon CG, Abdo C et al. Disorders of Orgasm and Ejaculation in Men. J Sex Med 2010; 7: 1668-1686
    CrossrefPubMedGoogle Scholar
  • 3 Waldinger MD. Premature ejaculation: different pathophysiologies and etiologies determine its treatment. J Sex Marital Ther 2008; 34: 1-13
    CrossrefPubMedGoogle Scholar
  • 4 Köhn FM. Wenn Männer zu früh kommen. MMW-fortschr Med 2003; 46: 912-916
    PubMedGoogle Scholar
  • 5 Porst H, Montorsi F Rosen RC et al. The Premature Ejaculation Prevalence and Attitudes (PEPA) Survey: Prevalence. Comorbidities, and Professional Help-Seeking. Eur Urol 2007; 51: 816-824
    Google Scholar
  • 6 Althof SE, Abdo CH, Dean J et al. International Society for Sexual Medicine’s guidelines for the diagnosis and treatment of premature ejaculation. J Sex Med 2010; 7: 2947-2969
    CrossrefPubMedGoogle Scholar
  • 7 Hatzimouratidis K, Amar E, Eardley I et al. Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation. Eur Urol 2010; DOI: 10.1016/j.eururo.2010.02.020.
    PubMedGoogle Scholar
  • 8 Kreutzer N, Sommer F, Klotz T et al. Aktuel Urol 2001; 32: 435-438
    Artikel in Thieme ConnectPubMed
  • 9 The Alza Corporation . Multi country concept evaluation and assessment of PE incidence study. Ref Type: Data File 2002
    Google Scholar
  • 10 Mathers MJ, Schmitges J, Klotz T et al. Introduction Into the Diagnostics and Treatment of Premature Ejaculation. Dtsch Arztebl 2007; 104: A-3475
    PubMedGoogle Scholar
  • 11 Laumann EO, Nicolosi A, Glasser DB et al. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res 2005; 17: 39-57
    CrossrefPubMedGoogle Scholar
  • 12 Waldinger MD, McIntosh J, Schweitzer DH. A five-nation survey to assess the distribution of the intravaginal ejaculatory latency time among the general male population. J Sex Med 2009; 6: 2888-2889
    CrossrefPubMedGoogle Scholar
  • 13 Jannini EA, Lenzi A. Epidemiology of premature ejaculation. Curr Opin Urol 2005; 15: 399-403
    PubMed
  • 14 Abdel-Hamid IA. Pharmacologic treatment of rapid ejaculation: levels of evidencebased review. Curr Clin Pharmacol1 2006; 243-254
    PubMedGoogle Scholar
  • 15 Waldinger MD, Quinn P, Dilleen M et al. A multinational population survey of intravaginal ejaculation latency time. J Sex Med 2005; 2: 492-497
    CrossrefPubMedGoogle Scholar
  • 16 Schapiro B. Premature ejaculation. A review of 1130 cases. J Urol 1943; 50: 374-379
    PubMedGoogle Scholar
  • 17 Waldinger MD, Berendsen HH, Blok BF et al. Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: the involvement of the serotonergic system. Behav Brain Res 1998; 92: 111-118
    CrossrefPubMedGoogle Scholar
  • 18 Jern P, Santtila P, Witting K et al. Premature and delayed ejaculation: genetic and environmental effects in a population-based sample of finish twins. J Sex Med 2007; 4: 1739-1749
    CrossrefPubMedGoogle Scholar
  • 19 Janssen PK, Bakker SC, Réthelyi J. Serotonin transporter promoter region (5-HTTLPR) polymorphism is associated with the intravaginal ejaculation latency time in Dutch men with lifelong premature ejaculation. J Sex Med Jan 2009; 6: 276-284
    CrossrefPubMedGoogle Scholar
  • 20 Semans JH. Premature ejaculation: A new approch. S Afr Med J 1956; 49: 353-358
    PubMedGoogle Scholar
  • 21 Masters WH, Johnson VE. Human sexual inadequacy. Boston, MA: Little Brown; 1970
    Google Scholar
  • 22 Giuliano F, Clément P. Serotonin and premature ejaculation: from physiology to patient management. Eur Urol 2006; 50: 454-466
    CrossrefPubMedGoogle Scholar
  • 23 Giuliano F, Clement P. Neuroanatomy and physiology of ejaculation. Ann Rev Sex Res 2005; 16: 190-216
    PubMedGoogle Scholar
  • 24 Pfaus JG. Pathways of sexual desire. J Sex Med 2009; 6: 1506-1533
    CrossrefPubMedGoogle Scholar
  • 25 Giuliano F, Hellstrom WJ. The pharmacological treatment of premature ejaculation. BJU Int 2008; 102: 668-675
    CrossrefPubMedGoogle Scholar
  • 26 Abdel-Hamid IA. Pharmacologic treatment of rapid ejaculation: levels of evidencebased review. Curr Clin Pharmacol 2006; 243-254
    PubMedGoogle Scholar
  • 27 Salonia A, Saccà A, Briganti A et al. Quantative sensory testing of peripheral thresholds in patients with lifelong premature ejaculation: A case-controlled study. J Sex Med 2009; 6: 1755-1762
    CrossrefPubMedGoogle Scholar
  • 28 Rowland DL. Psychophysiology of ejaculatory function and dysfunction. World J Urol 2008; 23: 82-88
    PubMedGoogle Scholar
  • 29 Waldinger MD. Lifelong premature ejaculation: from authority-based to evidence-based medicine. BJU Int 2004; 93: 201-207
    CrossrefPubMedGoogle Scholar
  • 30 McMahon CG. Clinical trail methodology in premature ejaculation observational, interventional, and treatment preference studies – part 1 – defining and selecting the study population. J Sex Med 2008; 5: 1805-1816
    CrossrefPubMedGoogle Scholar
  • 31 Rosen RC, McMahon CG, Niederberger C et al. Correlates to the clinical diagnosis of premature ejaculation: results from a large observational study of men and their partners. J Urol 2007; 177: 1059-1064
    CrossrefPubMedGoogle Scholar
  • 32 Patrick DL, Giuliano F, Ho KF et al. The Premature Ejaculation Profile: validation of self-reported outcome measures for research and practise. BJU Int 2009; 103: 358-364
    CrossrefPubMedGoogle Scholar
  • 33 Althof S, Rosen R, Symonds T et al. Development and validation of a new questionnaire to assess sexual satisfaction, control, and distress associated with premature ejaculation. J Sex Med 2006; 3: 465-475
    CrossrefPubMedGoogle Scholar
  • 34 Sommer F, Korda B, Mathers MJ et al. Ejaculatio praecox. 1. Auflage– Bremen: UNI MED; 2010
    Google Scholar
  • 35 Morales A, Barada J, Wyllie MG. A review of the current status of topical treatments for premature ejaculation. BJI Int 2007; 100: 493-501
    PubMedGoogle Scholar
  • 36 Hawton K, Catalan J, Faff J. Sex therapy for erectile dysfunction: characteristics of couples, treatment outcome, and prognostic factors. Arch Sex Behav 1992; 21: 161-175
    CrossrefPubMedGoogle Scholar
  • 37 Sadeghi-Nejad H, Watson R. Premature ejaculation: current medical treatment and new directions (CME). J Sex Med 2008; 5: 1037-1050
    CrossrefPubMedGoogle Scholar
  • 38 Waldinger MD. Premature ejaculation: definition and drug treatment. Drugs 2007; 67: 547-568
    CrossrefPubMedGoogle Scholar
  • 39 Waldinger MD, Zwinderman AH, Schweitzer DH et al. Relevance of methological disegne for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analyse. Int J Impot Res 2004; 16: 369-381
    CrossrefPubMedGoogle Scholar
  • 40 Mathers MJ, Klotz T, Roth S et al. Safety and efficacy of Vardenafil versus sertraline in the treatment of premature ejaculation: a randomised, prospective and crossover study. Andrologia 2009; 41: 169-175
    CrossrefPubMedGoogle Scholar
  • 41 Porst H, McMahon CG, Althof SE et al. Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: integrated analyses of two phase 3 Dapoxetine trails. J Sex Med 2010; 7: 2231-2242
    CrossrefPubMedGoogle Scholar
  • 42 Sommer F, Klotz T, Mathers MJ. Treatment of premature ejaculation: A comparative vardenafil and SSRI crossover study. J Urol 2005; 173: 202
    CrossrefPubMedGoogle Scholar
  • 43 Safarinejad MR, Hosseini SY. Safety and efficacy of tramadol in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. J Clin Psychopharmacol 2006; 26: 27-31
    CrossrefPubMedGoogle Scholar
  • 44 Cavallini G. Alpha-1 blockade pharmacotherapy in privative psychogenic premature ejaculation resistant to psychotherapy. Eur Urol 1995; 28: 126-130
    PubMedGoogle Scholar
  • 45 Gabuev A, Oelke M. Latest Trends and Recommendations on Epidemiology, Diagnosis, and Treatment of Benign Prostatic Hyperplasia (BPH). Aktuel Urol 2011; 42: 167-178
    Artikel in Thieme ConnectPubMedGoogle Scholar